

Gastric Cancer - Pipeline Insight, 2021

<https://marketpublishers.com/r/G5CE190A901EEN.html>

Date: July 2021

Pages: 60

Price: US\$ 3,000.00 (Single User License)

ID: G5CE190A901EEN

Abstracts

This report can be delivered to the clients within 7-10 Business Days

DelveInsight's, "Gastric Cancer - Pipeline Insight, 2021," report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Gastric Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Gastric Cancer Understanding

Gastric Cancer: Overview

Stomach cancer is cancer that starts anywhere inside the stomach or the stomach wall. It's also called gastric cancer. Stomach cancer is more common in older people. Around 50 out of 100 cases (around 50%) occur in people aged 75 or over. It is more common in men than women. Many stomach cancers are linked to lifestyle or environmental factors, including diet. Stomach cancer is linked with a bacteria that lives in the stomach called *Helicobacter pylori*. But not everyone with *Helicobacter pylori* will develop stomach cancer. The most common symptoms of stomach cancer include: difficulty swallowing (dysphagia), weight loss, indigestion (dyspepsia) that doesn't go away, feeling full after eating small amounts, feeling or being sick, and tiredness due to low red blood cells (anaemia). There are different types of treatment for patients with

gastric cancer. Seven types of standard treatment are used: Surgery, Endoscopic mucosal resection, Chemotherapy, Radiation therapy, Chemoradiation, Targeted therapy, and Immunotherapy.

'Gastric Cancer - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gastric Cancer pipeline landscape is provided which includes the disease overview and Gastric Cancer treatment guidelines. The assessment part of the report embraces, in depth Gastric Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gastric Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Gastric Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Gastric Cancer.

Gastric Cancer Emerging Drugs Chapters

This segment of the Gastric Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Gastric Cancer Emerging Drugs

IBI308: Innovent Biologics

IBI308 is a fully human monoclonal antibody that blocking programmed death protein-1. Innovent holds the global intellectual property rights of IBI308. Currently IBI308 has been approved for marketing by the NMPA. Acting as an immune checkpoint inhibitor by targeting PD-1, IBI308 boosts the immune response against tumor cells and inhibits the immune escape of tumor cells. Currently, it is in Phase III stage of clinical trial

evaluation to treat gastric cancer.

HLX10: Henlix Biotech

It is a recombinant Humanised Anti-PD-1 Monoclonal Antibody Injection independently researched and developed by Henlius, is for the treatment of various solid tumors and can be applied in combination with other products for immuno-oncology therapy. Currently, it is in Phase III stage of clinical trial evaluation to treat gastric cancer.

Pamiparib: BeiGene

It is an investigational small molecule inhibitor of the PARP1 and PARP2 enzymes that is being evaluated as a potential monotherapy and in combination with other therapies to treat various solid tumors. Pamiparib's early compound name was BGB-290. Currently, it is in Phase II stage of clinical trial evaluation to treat gastric cancer.

Further product details are provided in the report.....

Gastric Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Gastric Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Gastric Cancer

There are approx. 100+ key companies which are developing the therapies for Gastric Cancer. The companies which have their Gastric Cancer drug candidates in the most advanced stage, i.e. phase III include, Innovent Biologics.

Phases

DelveInsight's report covers around 100+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Gastric Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Gastric Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gastric Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gastric Cancer drugs.

Gastric Cancer Report Insights

Gastric Cancer Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Gastric Cancer Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Gastric Cancer drugs?

How many Gastric Cancer drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gastric Cancer?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Gastric Cancer therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Gastric Cancer and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Innovent Biologics

Henlix Biotech

BeiGene

Hanmi Pharmaceutical Company Limited

Hutchison Medipharma Limited

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Russian Pharmaceutical Technologies

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Idience

AnewPharma

MedPacto, Inc.

Five Prime Therapeutics, Inc.

Genentech

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Cellid Co., Ltd.

Nanjing Legend Biotech Co.

Eisai

Jiangsu Hengrui Medicine Co.

SYZ Cell Therapy Co.

LintonPharm Co.,Ltd.

Macrogenics

OncoTherapy Science

Avid Bioservices

Taizhou EOC Pharma Co., Ltd.

Bristol-Myers Squibb

Carsgen Therapeutics, Ltd.

Chengdu Kanghong Biotech Co., Ltd.

Ganymed Pharmaceuticals

Merck Sharp & Dohme Corp.

NextCure, Inc.

AstraZeneca

Pfizer

Pieris Pharmaceuticals, Inc.

Ambrx, Inc.

Merus N.V.

GeneQuantum Healthcare (Suzhou) Co., Ltd.

Highlight Therapeutics

Qilu Pharmaceutical Co., Ltd.

Green Cross Corporation

Imugene Limited

Vedanta Biosciences, Inc.

Acepodia Biotech Inc.

Keymed Biosciences Co.Ltd

Bold Therapeutics, Inc.

Regeneron Pharmaceuticals

Celon Pharma SA

Inhibrx, Inc.

HiberCell, Inc.

Treos Bio

Key Products

IBI308

HLX10

Pamiparib

FLX475

Volitinib

IBI-310

Anlotinib

Alofanib

DP303c

IDX-1197

HLX22

CM082

TEW-7197

Bemarituzumab

Atezolizumab

KN026

BVAC-B

LCAR-C18S

Lenvatinib

SHR6390

Camrelizumab

MASCT-I

Catumaxomab

INCMGA00012

OTSGC-A24

Bavituximab

Telatinib

BMS-986213

AB011

KH903

Zolbetuximab

Epacadostat

NC410

Durvalumab

Crizotinib

PRS-343

ARX788

MCLA-129

GQ1001

BO-112

QL1604

GC1118

IMU-131

VE800

ACE1702

CMG901

BOLD-100

89Zr?DFO?REGN3504

CPL304110

INBRX-106

HC-5404-FU

PolyPEPI 1311

Contents

- Introduction
- Executive Summary
- Gastric Cancer: Overview
 - Causes
 - Mechanism of Action
 - Signs and Symptoms
 - Diagnosis
 - Disease Management
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- Late Stage Products (Phase III)
 - Comparative Analysis
- IBI308: Innovent Biologics
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Mid Stage Products (Phase II)
 - Comparative Analysis
- Pamiparib: BeiGene
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....

- Early Stage Products (Phase I)
 - Comparative Analysis
- HC 5404 FU: HiberCell
 - Product Description
 - Research and Development

Product Development Activities
Drug profiles in the detailed report.....
Preclinical and Discovery Stage Products
 Comparative Analysis
PolyPEPI 1311: Treos Bio
 Product Description
 Research and Development
 Product Development Activities
Drug profiles in the detailed report.....

Inactive Products
 Comparative Analysis
Gastric Cancer Key Companies
Gastric Cancer Key Products
Gastric Cancer- Unmet Needs
Gastric Cancer- Market Drivers and Barriers
Gastric Cancer- Future Perspectives and Conclusion
Gastric Cancer Analyst Views
Gastric Cancer Key Companies
Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Gastric Cancer
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Gastric Cancer
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Gastric Cancer - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/G5CE190A901EEN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G5CE190A901EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970